REVIVA PHARMACEUTICALS HOLDINGS, INC.

Reviva Pharmaceuticals Holdings, Inc. (Nasdaq: RVPH) is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, psychiatric conditions, and metabolic diseases. The company became publicly traded following a SPAC merger completed in late 2019, with the 10-Q filing dated January 10, 2020 representing one of its first quarterly reports as a combined public entity. The filing, bearing accession number 0001104659-20-003044, reflects the company's status in the healthcare and biopharmaceutical sector during its early post-merger period. Full filing history, deal timelines, and sponsor data for RVPH are available on SpacDesk — sign up at SpacDesk.com to access the complete dataset.